Two recent M&A events reflect divergent responses to common challenges facing specialty pharma players. However different, both repudiate heavy reliance on innovative drug R&D in favor of apparently less risky initiatives with measurable short-term gains.
Endo Pharmaceuticals Holding Inc.'s transformative agreement to buy American Medical Systems Holdings Inc., a medical devices manufacturer, for $2.9...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?